Atossa Therapeutics, Inc. (ATOS )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ATOS
- Company Atossa Therapeutics, Inc.
- Price $5.5
- Changes Percentage -1.61
- Change -0.09
- Day Low $4.91
- Day High $5.85
- Year High $19.35
- Year Low $4.91
- Market Cap $47,362,700
- Price Avg 50 EMA (D) $10.34
- Price Avg 200 EMA (D) $12.16
- Exchange NASDAQ
- Volume 466,264
- Average Volume 100,379
- Open $5.6
- Previous Close $5.59
- EPS -3.45
- PE -1.59
- Earnings Announcement 2026-04-01 12:00:00
- Shares Outstanding $8,611,400
Company brief: ATOSSA THERAPEUTICS, INC. (ATOS )
- Healthcare
- Biotechnology
- Dr. Steven C. Quay FCAP, M.D., Ph.D.
- https://www.atossatherapeutics.com
- US
- N/A
- 11-08-2012
- US04962H5063
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.